{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:26:02Z","timestamp":1787660762728,"version":"build-2736575974"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30AG066508"],"award-info":[{"award-number":["P30AG066508"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG034924"],"award-info":[{"award-number":["R01AG034924"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["T32NS105583"],"award-info":[{"award-number":["T32NS105583"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-75895-9","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:13:09Z","timestamp":1784743989000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Distinct Filament Conformation for Receptor-Bound Amyloid-\u03b2 from Alzheimer\u2019s Disease Brain"],"prefix":"10.1038","volume":"17","author":[{"given":"Mikhail A.","family":"Kostylev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Butan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham P.","family":"Roseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanina","family":"Arab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5985-7168","authenticated-orcid":false,"given":"Ruibing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4708-8479","authenticated-orcid":false,"given":"Pallavi","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8188-3092","authenticated-orcid":false,"given":"Stephen M.","family":"Strittmatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"75895_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","volume":"7","author":"DS Knopman","year":"2021","unstructured":"Knopman, D. S. et al. Alzheimer disease. Nat. Rev. Dis. Prim. 7, 33 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"75895_CR2","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long, J. M. & Holtzman, D. M. Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179, 312\u2013339 (2019).","journal-title":"Cell"},{"key":"75895_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s Disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"75895_CR4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. J. Am. Med. Assoc. 330, 512\u2013527 (2023).","journal-title":"J. Am. Med. Assoc."},{"key":"75895_CR5","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/ana.26071","volume":"89","author":"RC Petersen","year":"2021","unstructured":"Petersen, R. C. et al. NIA-AA Alzheimer\u2019s disease framework: clinical characterization of stages. Ann. Neurol. 89, 1145\u20131156 (2021).","journal-title":"Ann. Neurol."},{"key":"75895_CR6","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol. Med. 8, 595\u2013608 (2016).","journal-title":"EMBO Mol. Med."},{"key":"75895_CR7","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel, H. et al. The amyloid-beta pathway in Alzheimer\u2019s Disease. Mol. Psychiatry 26, 5481\u20135503 (2021).","journal-title":"Mol. Psychiatry"},{"key":"75895_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/416535a","volume":"416","author":"DM Walsh","year":"2002","unstructured":"Walsh, D. M. et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535\u2013539 (2002).","journal-title":"Nature"},{"key":"75895_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nn.3028","volume":"15","author":"I Benilova","year":"2012","unstructured":"Benilova, I., Karran, E. & De Strooper, B. The toxic Abeta oligomer and Alzheimer\u2019s disease: an emperor in need of clothes. Nat. Neurosci. 15, 349\u2013357 (2012).","journal-title":"Nat. Neurosci."},{"key":"75895_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1126\/science.abm7285","volume":"375","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. Cryo-EM structures of amyloid-beta 42 filaments from human brains. Science 375, 167\u2013172 (2022).","journal-title":"Science"},{"key":"75895_CR11","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1038\/s41593-023-01484-4","volume":"26","author":"M Zielinski","year":"2023","unstructured":"Zielinski, M. et al. Cryo-EM of Abeta fibrils from mouse models find tg-APP(ArcSwe) fibrils resemble those found in patients with sporadic Alzheimer\u2019s disease. Nat. Neurosci. 26, 2073\u20132080 (2023).","journal-title":"Nat. Neurosci."},{"key":"75895_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00401-022-02533-1","volume":"145","author":"Y Yang","year":"2023","unstructured":"Yang, Y. et al. Cryo-EM structures of amyloid-beta filaments with the Arctic mutation (E22G) from human and mouse brains. Acta Neuropathol. 145, 325\u2013333 (2023).","journal-title":"Acta Neuropathol."},{"key":"75895_CR13","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","volume":"95","author":"MP Lambert","year":"1998","unstructured":"Lambert, M. P. et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95, 6448\u20136453 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75895_CR14","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1021\/bi802046n","volume":"48","author":"L Yu","year":"2009","unstructured":"Yu, L. et al. Structural characterization of a soluble amyloid beta-peptide oligomer. Biochemistry 48, 1870\u20131877 (2009).","journal-title":"Biochemistry"},{"key":"75895_CR15","doi-asserted-by":"publisher","first-page":"17415","DOI":"10.1074\/jbc.M115.643577","volume":"290","author":"MA Kostylev","year":"2015","unstructured":"Kostylev, M. A. et al. Prion-protein-interacting amyloid-beta oligomers of high molecular weight are tightly correlated with memory impairment in multiple alzheimer mouse models. J. Biol. Chem. 290, 17415\u201317438 (2015).","journal-title":"J. Biol. Chem."},{"key":"75895_CR16","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/j.neuron.2023.04.007","volume":"111","author":"AM Stern","year":"2023","unstructured":"Stern, A. M. et al. Abundant Abeta fibrils in ultracentrifugal supernatants of aqueous extracts from Alzheimer\u2019s disease brains. Neuron 111, 2012\u20132020 e2014 (2023).","journal-title":"Neuron"},{"key":"75895_CR17","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/nature07761","volume":"457","author":"J Lauren","year":"2009","unstructured":"Lauren, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W. & Strittmatter, S. M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 1128\u20131132 (2009).","journal-title":"Nature"},{"key":"75895_CR18","doi-asserted-by":"publisher","first-page":"6042","DOI":"10.1074\/jbc.RA118.006252","volume":"294","author":"LM Smith","year":"2019","unstructured":"Smith, L. M., Kostylev, M. A., Lee, S. & Strittmatter, S. M. Systematic and standardized comparison of reported amyloid-beta receptors for sufficiency, affinity, and Alzheimer\u2019s disease relevance. J. Biol. Chem. 294, 6042\u20136053 (2019).","journal-title":"J. Biol. Chem."},{"key":"75895_CR19","doi-asserted-by":"crossref","unstructured":"Smith L. M. & Strittmatter S. M. Binding sites for amyloid-beta oligomers and synaptic toxicity. Csh Perspect. Med. 7, a024075 (2017).","DOI":"10.1101\/cshperspect.a024075"},{"key":"75895_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.biopsych.2017.11.020","volume":"83","author":"SA Purro","year":"2018","unstructured":"Purro, S. A., Nicoll, A. J. & Collinge, J. Prion protein as a toxic acceptor of amyloid-beta oligomers. Biol. Psychiatry 83, 358\u2013368 (2018).","journal-title":"Biol. Psychiatry"},{"key":"75895_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.celrep.2018.12.021","volume":"26","author":"EC Gunther","year":"2019","unstructured":"Gunther, E. C. et al. Rescue of transgenic Alzheimer\u2019s pathophysiology by polymeric cellular prion protein antagonists. Cell Rep. 26, 145\u2013158.e148 (2019).","journal-title":"Cell Rep."},{"key":"75895_CR22","doi-asserted-by":"publisher","first-page":"6367","DOI":"10.1523\/JNEUROSCI.0395-10.2010","volume":"30","author":"DA Gimbel","year":"2010","unstructured":"Gimbel, D. A. et al. Memory impairment in transgenic Alzheimer mice requires cellular prion protein.  J. Neurosci. 30, 6367\u20136374 (2010).","journal-title":"J. Neurosci."},{"key":"75895_CR23","doi-asserted-by":"publisher","first-page":"9207","DOI":"10.1523\/JNEUROSCI.0722-17.2017","volume":"37","author":"SV Salazar","year":"2017","unstructured":"Salazar, S. V. et al. Conditional deletion of Prnp rescues behavioral and synaptic deficits after disease onset in transgenic Alzheimer\u2019s disease.  J. Neurosci. 37, 9207\u20139221 (2017).","journal-title":"J. Neurosci."},{"key":"75895_CR24","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/acn3.730","volume":"6","author":"TO Cox","year":"2019","unstructured":"Cox, T. O. et al. Anti-PrP(C) antibody rescues cognition and synapses in transgenic alzheimer mice. Ann. Clin. Transl. Neurol. 6, 554\u2013574 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"75895_CR25","doi-asserted-by":"publisher","first-page":"28460","DOI":"10.1074\/jbc.M114.584342","volume":"289","author":"LT Haas","year":"2014","unstructured":"Haas, L. T., Kostylev, M. A. & Strittmatter, S. M. Therapeutic molecules and endogenous ligands regulate the interaction between brain cellular prion protein (PrPC) and metabotropic glutamate receptor 5 (mGluR5). J. Biol. Chem. 289, 28460\u201328477 (2014).","journal-title":"J. Biol. Chem."},{"key":"75895_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.celrep.2017.06.023","volume":"20","author":"LT Haas","year":"2017","unstructured":"Haas, L. T. et al. Silent allosteric modulation of mGluR5 maintains glutamate signaling while rescuing Alzheimer\u2019s mouse phenotypes. Cell Rep. 20, 76\u201388 (2017).","journal-title":"Cell Rep."},{"key":"75895_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s13195-023-01345-z","volume":"15","author":"A Stoner","year":"2023","unstructured":"Stoner, A. et al. Neuronal transcriptome, tau and synapse loss in Alzheimer\u2019s knock-in mice require prion protein. Alzheimers Res. Ther. 15, 201 (2023).","journal-title":"Alzheimers Res. Ther."},{"key":"75895_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abi8593","volume":"14","author":"J Spurrier","year":"2022","unstructured":"Spurrier, J. et al. Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q. Sci. Transl. Med. 14, eabi8593 (2022).","journal-title":"Sci. Transl. Med."},{"key":"75895_CR29","first-page":"3660","volume":"27","author":"JK Heiss","year":"2017","unstructured":"Heiss, J. K. et al. Early activation of experience-independent dendritic spine turnover in a mouse model of Alzheimer\u2019s disease. Cereb. Cortex 27, 3660\u20133674 (2017).","journal-title":"Cereb. Cortex"},{"key":"75895_CR30","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/brain\/awv356","volume":"139","author":"LT Haas","year":"2016","unstructured":"Haas, L. T. et al. Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer\u2019s disease. Brain 139, 526\u2013546 (2016).","journal-title":"Brain"},{"key":"75895_CR31","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.neuron.2013.06.036","volume":"79","author":"JW Um","year":"2013","unstructured":"Um, J. W. et al. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron 79, 887\u2013902 (2013).","journal-title":"Neuron"},{"key":"75895_CR32","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.molcel.2018.10.009","volume":"72","author":"MA Kostylev","year":"2018","unstructured":"Kostylev, M. A. et al. Liquid and hydrogel phases of PrP(C) linked to conformation shifts and triggered by Alzheimer\u2019s amyloid-beta oligomers. Mol. Cell 72, 426\u2013443.e412 (2018).","journal-title":"Mol. Cell"},{"key":"75895_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","volume":"20","author":"L Soderberg","year":"2023","unstructured":"Soderberg, L. et al. Lecanemab, aducanumab, and gantenerumab-binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s disease. Neurotherapeutics 20, 195\u2013206 (2023).","journal-title":"Neurotherapeutics"},{"key":"75895_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23507-z","volume":"12","author":"L Amin","year":"2021","unstructured":"Amin, L. & Harris, D. A. Abeta receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat. Commun. 12, 3451 (2021).","journal-title":"Nat. Commun."},{"key":"75895_CR35","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1021\/cn500019c","volume":"5","author":"K Nieznanski","year":"2014","unstructured":"Nieznanski, K., Surewicz, K., Chen, S., Nieznanska, H. & Surewicz, W. K. Interaction between prion protein and Abeta amyloid fibrils revisited. ACS Chem. Neurosci. 5, 340\u2013345 (2014).","journal-title":"ACS Chem. Neurosci."},{"key":"75895_CR36","doi-asserted-by":"publisher","first-page":"16858","DOI":"10.1074\/jbc.M117.789990","volume":"292","author":"E Bove-Fenderson","year":"2017","unstructured":"Bove-Fenderson, E., Urano, R., Straub, J. E. & Harris, D. A. Cellular prion protein targets amyloid-beta fibril ends via its C-terminal domain to prevent elongation. J. Biol. Chem. 292, 16858\u201316871 (2017).","journal-title":"J. Biol. Chem."},{"key":"75895_CR37","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/s41594-024-01252-3","volume":"31","author":"A Fernandez","year":"2024","unstructured":"Fernandez, A. et al. Cryo-EM structures of amyloid-beta and tau filaments in Down syndrome. Nat. Struct. Mol. Biol. 31, 903\u2013909 (2024).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"75895_CR38","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-024-07691-8","volume":"631","author":"S Lesne","year":"2024","unstructured":"Lesne, S. et al. Retraction Note: aspecific amyloid-beta protein assembly in the brain impairs memory. Nature 631, 240 (2024).","journal-title":"Nature"},{"key":"75895_CR39","doi-asserted-by":"publisher","first-page":"13406","DOI":"10.1021\/acs.jpcb.1c08604","volume":"125","author":"J Mahato","year":"2021","unstructured":"Mahato, J. et al. Investigation of structural heterogeneity in individual amyloid fibrils using polarization-resolved microscopy. J. Phys. Chem. B 125, 13406\u201313414 (2021).","journal-title":"J. Phys. Chem. B"},{"key":"75895_CR40","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.1021\/acs.jpcb.2c04797","volume":"126","author":"S Banerjee","year":"2022","unstructured":"Banerjee, S. et al. Nanoscale infrared spectroscopy identifies structural heterogeneity in individual amyloid fibrils and prefibrillar aggregates. J. Phys. Chem. B 126, 5832\u20135841 (2022).","journal-title":"J. Phys. Chem. B"},{"key":"75895_CR41","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/nn.3178","volume":"15","author":"JW Um","year":"2012","unstructured":"Um, J. W. et al. Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci. 15, 1227\u20131235 (2012).","journal-title":"Nat. Neurosci."},{"key":"75895_CR42","doi-asserted-by":"publisher","first-page":"15095","DOI":"10.1074\/jbc.M110.199356","volume":"286","author":"WQ Zou","year":"2011","unstructured":"Zou, W. Q. et al. Amyloid-beta42 interacts mainly with insoluble prion protein in the Alzheimer brain. J. Biol. Chem. 286, 15095\u201315105 (2011).","journal-title":"J. Biol. Chem."},{"key":"75895_CR43","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/brain\/awt375","volume":"137","author":"F Dohler","year":"2014","unstructured":"Dohler, F. et al. High molecular mass assemblies of amyloid-beta oligomers bind prion protein in patients with Alzheimer\u2019s disease. Brain 137, 873\u2013886 (2014).","journal-title":"Brain"},{"key":"75895_CR44","doi-asserted-by":"publisher","first-page":"e32014","DOI":"10.1371\/journal.pone.0032014","volume":"7","author":"D Sehlin","year":"2012","unstructured":"Sehlin, D. et al. Large aggregates are the major soluble Abeta species in AD brain fractionated with density gradient ultracentrifugation. PLoS ONE 7, e32014 (2012).","journal-title":"PLoS ONE"},{"key":"75895_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/mas.21775","volume":"44","author":"NV Zakharova","year":"2025","unstructured":"Zakharova, N. V. et al. Mass spectrometric studies of the variety of beta-amyloid proteoforms in Alzheimer\u2019s disease. Mass Spectrom. Rev. 44, 3\u201321 (2025).","journal-title":"Mass Spectrom. Rev."},{"key":"75895_CR46","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1471-4159.2007.04759.x","volume":"103","author":"H Englund","year":"2007","unstructured":"Englund, H. et al. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J. Neurochem. 103, 334\u2013345 (2007).","journal-title":"J. Neurochem."},{"key":"75895_CR47","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","volume":"76","author":"RB Demattos","year":"2012","unstructured":"Demattos, R. B. et al. A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer\u2019s disease mice. Neuron 76, 908\u2013920 (2012).","journal-title":"Neuron"},{"key":"75895_CR48","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1002\/acn3.52042","volume":"11","author":"RB Vukmir","year":"2024","unstructured":"Vukmir, R. B. Amyloid-related imaging abnormalities (ARIA): diagnosis, management, and care in the setting of amyloid-modifying therapy. Ann. Clin. Transl. Neurol. 11, 1669\u20131680 (2024).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"75895_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine, T. J. et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 123, 1\u201311 (2012).","journal-title":"Acta Neuropathol."},{"key":"75895_CR50","doi-asserted-by":"publisher","first-page":"e59820","DOI":"10.1371\/journal.pone.0059820","volume":"8","author":"S Dornieden","year":"2013","unstructured":"Dornieden, S. et al. Characterization of a single-chain variable fragment recognizing a linear epitope of abeta: a biotechnical tool for studies on Alzheimer\u2019s disease? PLoS ONE 8, e59820 (2013).","journal-title":"PLoS ONE"},{"key":"75895_CR51","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0014-5793(97)01330-6","volume":"417","author":"R Zahn","year":"1997","unstructured":"Zahn, R., von Schroetter, C. & Wuthrich, K. Human prion proteins expressed in Escherichia coli and purified by high-affinity column refolding. FEBS Lett. 417, 400\u2013404 (1997).","journal-title":"FEBS Lett."},{"key":"75895_CR52","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.pep.2005.01.016","volume":"41","author":"FW Studier","year":"2005","unstructured":"Studier, F. W. Protein production by auto-induction in high density shaking cultures. Protein Expr. Purif. 41, 207\u2013234 (2005).","journal-title":"Protein Expr. Purif."},{"key":"75895_CR53","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.neuron.2019.07.014","volume":"104","author":"R Tian","year":"2019","unstructured":"Tian, R. et al. CRISPR Interference-Based Platform for Multimodal Genetic Screens in Human iPSC-Derived Neurons. Neuron 104, 239\u2013255.e212 (2019).","journal-title":"Neuron"},{"key":"75895_CR54","doi-asserted-by":"publisher","DOI":"10.21769\/BioProtoc.4393","volume":"12","author":"BJ Heymann","year":"2022","unstructured":"Heymann, B. J. Bsoft: image processing for structural biology. Bio Protoc. 12, e4393 (2022).","journal-title":"Bio Protoc."},{"key":"75895_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102071","volume":"298","author":"R Liang","year":"2022","unstructured":"Liang, R., Tian, Y. & Viles, J. H. Cross-seeding of WT amyloid-beta with Arctic but not Italian familial mutants accelerates fibril formation in Alzheimer\u2019s disease. J. Biol. Chem. 298, 102071 (2022).","journal-title":"J. Biol. Chem."},{"key":"75895_CR56","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40478-021-01187-6","volume":"9","author":"A Ruiz-Riquelme","year":"2021","unstructured":"Ruiz-Riquelme, A. et al. Abeta43 aggregates exhibit enhanced prion-like seeding activity in mice. Acta Neuropathol. Commun. 9, 83 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"75895_CR57","doi-asserted-by":"crossref","unstructured":"Koloteva-Levine, N. et al. Amyloid particles facilitate surface-catalyzed cross-seeding by acting as promiscuous nanoparticles. Proc. Natl. Acad. Sci. USA 118, e2104148118 (2021).","DOI":"10.1073\/pnas.2104148118"},{"key":"75895_CR58","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.1074\/jbc.M116.764092","volume":"292","author":"KJ Korshavn","year":"2017","unstructured":"Korshavn, K. J. et al. Reduced lipid bilayer thickness regulates the aggregation and cytotoxicity of amyloid-beta. J. Biol. Chem. 292, 4638\u20134650 (2017).","journal-title":"J. Biol. Chem."},{"key":"75895_CR59","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.celrep.2014.02.031","volume":"7","author":"N Salvadores","year":"2014","unstructured":"Salvadores, N., Shahnawaz, M., Scarpini, E., Tagliavini, F. & Soto, C. Detection of misfolded Abeta oligomers for sensitive biochemical diagnosis of Alzheimer\u2019s disease. Cell Rep. 7, 261\u2013268 (2014).","journal-title":"Cell Rep."},{"key":"75895_CR60","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1021\/cn900015v","volume":"1","author":"E Hellstrand","year":"2010","unstructured":"Hellstrand, E., Boland, B., Walsh, D. M. & Linse, S. Amyloid beta-protein aggregation produces highly reproducible kinetic data and occurs by a two-phase process. ACS Chem. Neurosci. 1, 13\u201318 (2010).","journal-title":"ACS Chem. Neurosci."},{"key":"75895_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51294-w","volume":"15","author":"MJ Tehrani","year":"2024","unstructured":"Tehrani, M. J. et al. E22G Abeta40 fibril structure and kinetics illuminate how Abeta40 rather than Abeta42 triggers familial Alzheimer\u2019s. Nat. Commun. 15, 7045 (2024).","journal-title":"Nat. Commun."},{"key":"75895_CR62","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1017\/S1431927603445911","volume":"9","author":"DN Mastronarde","year":"2003","unstructured":"Mastronarde, D. N. SerialEM: a program for automated tilt series acquisition on tecnai microscopes using prediction of specimen position. Microsc. Microanal. 9, 1182\u20131183 (2003).","journal-title":"Microsc. Microanal."},{"key":"75895_CR63","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1042\/BCJ20210708","volume":"478","author":"D Kimanius","year":"2021","unstructured":"Kimanius, D., Dong, L., Sharov, G., Nakane, T. & Scheres, S. H. W. New tools for automated cryo-EM single-particle analysis in RELION-4.0. Biochem J. 478, 4169\u20134185 (2021).","journal-title":"Biochem J."},{"key":"75895_CR64","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1107\/S205225251801463X","volume":"6","author":"J Zivanov","year":"2019","unstructured":"Zivanov, J., Nakane, T. & Scheres, S. H. W. A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis. IUCrJ 6, 5\u201317 (2019).","journal-title":"IUCrJ"},{"key":"75895_CR65","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jsb.2015.08.008","volume":"192","author":"A Rohou","year":"2015","unstructured":"Rohou, A. & Grigorieff, N. CTFFIND4: fast and accurate defocus estimation from electron micrographs. J. Struct. Biol. 192, 216\u2013221 (2015).","journal-title":"J. Struct. Biol."},{"key":"75895_CR66","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1107\/S2052252520000081","volume":"7","author":"J Zivanov","year":"2020","unstructured":"Zivanov, J., Nakane, T. & Scheres, S. H. W. Estimation of high-order aberrations and anisotropic magnification from cryo-EM data sets in RELION-3.1. IUCrJ 7, 253\u2013267 (2020).","journal-title":"IUCrJ"},{"key":"75895_CR67","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ultramic.2013.06.004","volume":"135","author":"S Chen","year":"2013","unstructured":"Chen, S. et al. High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy. Ultramicroscopy 135, 24\u201335 (2013).","journal-title":"Ultramicroscopy"},{"key":"75895_CR68","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput Chem."},{"key":"75895_CR69","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"75895_CR70","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1107\/S2059798318006551","volume":"74","author":"PV Afonine","year":"2018","unstructured":"Afonine, P. V. et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr. D Struct. Biol. 74, 531\u2013544 (2018).","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"75895_CR71","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/pro.3786","volume":"29","author":"MG Prisant","year":"2020","unstructured":"Prisant, M. G., Williams, C. J., Chen, V. B., Richardson, J. S. & Richardson, D. C. New tools in MolProbity validation: CaBLAM for CryoEM backbone, UnDowser to rethink \u201cwaters,\u201d and NGL Viewer to recapture online 3D graphics. Protein Sci. 29, 315\u2013329 (2020).","journal-title":"Protein Sci."},{"key":"75895_CR72","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75895-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75895-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75895-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:02:31Z","timestamp":1787659351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75895-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75895"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75895-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"21 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.M.S. is a founder, receives consulting fees, and holds equity interest in Allyx Therapeutics, which seeks to develop mGluR5 and PrP\n                      C\n                      compounds for Alzheimer\u2019s disease. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8953"}}